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BACKGROUND: Cryptococcosis is one of the common 
opportunistic fungal infections among HIV infected patients living 
in Sub-Saharan Africa, including Ethiopia. The magnitude of the 
disease at Felege Hiwot Referral Hospital (FHRH) in particular 
and in Ethiopia at large is not well explored.  
METHODS: A retrospective document review and analysis was 
done on records of 137 HIV infected patients who visited FHRH 
ART clinic from 1 Sep to 30 Dec 2016 and had registered data on 
their sex, age, CD4 count and cryptococcal antigen screening 
result. The cryptoccocal antigen (CrAg) detection was done by the 
IMMY CrAg® LFA (Cryptococcal Antigen Lateral Flow Assay) kit 
from patient serum as per the manufacturer’s instruction. All data 
were entered, cleared, and analyzed using SPSS v20. Descriptive 
data analysis and cross tabulation were done to assess factors 
associated with cryptococcal antigenemia. Statistical significance 
was set at p-value less than or equal to 0.05. 
RESULTS: More than half of the participants, 54.7% (75/137), 
included in the study were females. The median age of the 
participants was 32.0 years (ranged: 8-52 years). The mean CD4 
count was 51.8 with SD of 26.3 (range 3-98). All the patients were 
HIV stage IV. The proportion of positive cryptococal antigen from 
serum test was at 11.7% (95% CI: 7.3-18.1%). The IMMY 
CrAg® LFA result was found statically associated with patient sex 
(p= 0.045). However, it was not associated with patient age group 
and the CD4 count (P>0.05) 
CONCLUSIONS: This study provided baseline data on the 
magnitude of cryptococcal antigenemia among HIV positive 
patients that is not touched before in the studied area. The results 
of the study showed that this opportunistic fungal infection is an 
important health concern among HIV patients. Further studies 
with sound design employing adequate sample size should be 
considered.  
KEYWORDS; Cryptococcal antigenemia, IMMY CrAg® LFA, 
Bahir Dar, Ethiopia 
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Increasing access to antiretroviral therapy (ART) 
has transformed the prognosis of HIV infected 
patients in resource-limited settings. However, 
treatment coverage remains relatively low, and 
HIV diagnosis occurs at a late stage. As a result, 
many patients continue to die of HIV-related 
opportunistic infections (OIs) in the weeks prior 
to, and months following initiation of ART (1, 2). 
Cryptococcus neoformans, a causative agent of 
cryptococcosis remain a common cause of 
infectious morbidity and mortality, especially 
among HIV-positive patients living in Sub-
Saharan Africa (3). Cryptococcal disease is one of 
the most important OIs, and a major contributor to 
this early mortality, accounting for between 13% 
and 44% of deaths among HIV infected people 
living in developing nations. In sub-Saharan 
Africa alone, there are more than 500,000 deaths 
each year due to cryptococcal meningitis (CM), 
which may exceed those attributed to tuberculosis 
(1). 
Cryptococcus is a type of fungus that lives in 
soil, especially soil that is contaminated with large 
amounts of bird droppings. Some people inhale 
the spores from the environment and never get 
sick, but in people with weak immune systems, the 
fungus can cause an infection. The only way a 
person can get sick from this fungus is by directly 
inhaling the agent from the environment, making 
it no person to person transmission (1,4). 
Cryptococcal infection is associated with a 
range of illness. In some people, it causes a lung 
infection similar to tuberculosis, or it can cause no 
symptoms at all. The incubation period is not 
known, but it is thought that the infection can 
remain dormant in the body for many years. In 
immunosuppressed people, particularly HIV-
infected once with CD4 counts less than 100, the 
infection can reactivate and spread throughout the 
body. When this happens, the infection usually 
presents as meningitis which is a common cause 
of death among HIV/AIDS patients (5). 
The case fatality rate in patients with 
cryptococcal meningitis, the commonest 
presentation of HIV-related cryptococcal disease 
in adults, remains unacceptably high, particularly 
in sub-Saharan Africa, between 35%-65%. This 
compares with 10%-20% in most developed 
countries. The main reason for this is a delay in 
presentation with diagnosis only when meningitis 
is advanced and treatment is less effective, mainly 
as a result of limited access to lumbar puncture 
(LP) and rapid diagnostic assays (1). 
There are three categories of methods that 
can be used to diagnose cryptococcal meningitis: 
India Ink microscopy, which can be used on 
cerebrospinal fluid (CSF); culture, which can be 
used on CSF or blood; and antigen detection. 
There are several methods to detect cryptococcal 
antigen in CSF or serum: latex agglutination (LA), 
enzyme immunoassay (EIA), and lateral flow 
assay (LFA) (6-8). A patient who tests positive for 
cryptococcal antigen can take oral fluconazole to 
help the body fight the early stage of the infection. 
This could prevent the infection from developing 
into meningitis (9). 
In Ethiopia, where there is poor surveillance 
system, there are few studies conducted on the 
level of cryptococcal infection and its associated 
risk factors (2,10-11). However, the data is 
missing in our study site where there are a number 
of HIV patients getting ART service in accordance 
with the national ART program. Some HIV 
patients in the study area get tested for 
cryptococcal infection during follow-up when 
there is suggestive clinical presentations.  Thus, 
the aim of this study was to assess the prevalence 
of cryptococcal antigenemia and its associated 
factors among HIV infected patients at Felege 
Hiwot Referral Hospital (FHRH) setting. 
 
MATERIALS AND METHODS 
 
Study design, setting and data collection: A 
retrospective record review was done on records 
of 137 HIV infected patients who were attending 
ART monitoring at FHRH ART clinic. The 
hospital is located in Bahir Dar town, which is the 
capital of Amhara National Regional State located 
565 km away from the capital Addis Ababa. The 
FHRH is a tertiary health care level hospital 
serving the population of Bahir Dar and remote 
areas of Northwest Ethiopia. The total population 
served by the hospital is about 12 million. In the 
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hospital, the ART clinic is operating under the 
National HIV Program of Ethiopia, under which 
patients are diagnosed for HIV and get ART 
treatment and follow-up services (CD4 count, 
liver and kidney function tests and hematologic 
evaluation) for free. 
HIV positive patients, regardless of their 
ART status, whose CD4 count was less than 100 
and had headache with signs suggestive of 
meningitis were screened for CrAg in the hospital 
(1). Taking this background, those HIV patients 
who visited the hospital’s ART clinic from 1 Sep 
to 30 Dec 2016 and had registered data on their 
sex, age, CD4 count and cryptococcal antigen 
screening result were included for analysis. Patient 
records that missed one of these variables were 
excluded from the study. Data were retrieved 
directly from laboratory registration logbook using 
data extraction sheet on 1to 10 January 2017. 
 
Cryptococcal antigen test: Although culture is 
the standard method for definitive diagnosis, 
detection of cryptococcal antigen in serum or 
cerebrospinal fluid is used for presumptive 
diagnosis. Cryptococcal antigen screening in 
peripheral blood is also recommended for HIV-
infected persons with CD4 cell counts <100/µl to 
reduce early deaths while receiving ART (6, 12). 
In the studied area, the cryptoccocal antigen 
(CrAg) detection was done by the IMMY 
CrAg® LFA (Cryptococcal Antigen Lateral Flow 
Assay) kit as per the manufacturer’s instruction. 
The IMMY CrAg® LFA is an 
immunochromatographic dipstick assay for the 
qualitative and semi-quantitative detection of 
cryptococcal antigen in serum, plasma, whole 
blood and cerebrospinal fluid (CSF). The 
CrAg® LFA is a prescription use laboratory assay 
which can aid in the diagnosis of cryptococcosis 
(6,12). In this study, from those patients who came 
with evidence of cryptococcal meningitis, 40µl 
serum was used to detect the CrAg. The serum and 
its one drop dilute were added into a test tube and 
the lateral flow device that is pre-coated with anti-
CrAg monoclonal antibodies and gold conjugated 
control antibodies was submerged with its white 
end. After ten minutes of incubation, the result 
was read and recorded. The antigen antibody 
complex forms a test line causing a visible line to 
form. The IMMY CrAg® LFA has sensitivity and 
specificity of 100% using serum (12-13). Patients 
found positive for CrAg were managed using 
fluconzole based antifungal treatment based on the 
recommended approach.  
 
Statistical analysis: All data were entered, 
cleared, and analyzed using SPSS statistical 
software package, Version 22.0. Descriptive data 
analysis was used to visualize differences within 
data, and cross tabulation was done to assess 
factors associated with cryptococcal antigen. 
Differences were considered significant when p-
value was less than or equal to 0.05. 
 
Ethical issues: Permission and ethical clearance 
were obtained from Amhara Regional Health 
Bureau Institutional Review Board (IRB) to utilize 
the data.  As the data was collected 
retrospectively, no patient details were linked to 





In this study, we analyzed the records of 137 HIV 
infected patients to assess their cryptococcal 
antigenemia. More than half of the participants, 
75(54.7%), were females. The median age of the 
participants was 32.0 years (ranged: 8-52 years). 
The mean CD4 count was at 51.8 with standard 
deviation of 26.3 (range 3-98). The proportion of 
positive cryptococal antigenemia from serum test 
was at 11.7% (95% CI: 7.3-18.1%) (Table1). 
Further, based on the WHO classification system, 
all of the HIV positive participants in this study 
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Table 1: Demographic and related clinical data of HIV patients screened for cryptococcal antigenemia at 
FHRH, Bahir Dar, 2016. 
 
 
Variable Frequency Percent 
Sex Male 62 45.3 
Female 75 54.7 
Total  137 100 
Age group in years 0-14 3 2.2 
15-24 11 8.0 
25-34 69 50.4 
35-44 38 27.7 
>44 16 11.7 
CD4 count/ µl 0-25 25 18.2 
26-50 46 33.6 
51-75 36 26.3 
76-100 30 21.9 
CrAg LFA result Positive 16 11.7 
Negative 121 88.3 
 
We found that the IMMY CrAg® LFA result was 
statically associated with patient sex (p= 0.045). 
However, it was not found associated with the 
patient age group and the CD4 count (P>0.05) 
(Table).  






No. Tested  
*CrAg LFA result  
P value  Positive n (%) Negative n (%)  
Patient Sex Male 62 11 (17.7) 51 (82.3)  
0.045 Female 75 5 (6.7) 70 (93.3) 
Age groups in 
years 
0-14 3 1 (33.3) 2 (66.7)  
 
0.276 
15-24 11 0 (0) 11 (100) 
25-34 69 7 (10.1) 62 (89.9) 
35-44 38 7 (18.4) 31 (81.6) 
>44 16 1 (6.3) 15 (93.7) 
CD4 count  0-25 25 3 (12) 22 (88)  
0.793 26-50 46 7 (15.2) 39 (84.8) 
51-75 36 3 (8.3) 33 (91.7) 
76-100 30 3 (10) 27 (90) 




Although the widespread availability of 
antiretroviral therapy (ART) in developed 
countries has helped reduce cryptococcal 
infections in these areas, it is still a major problem 
in developing countries, like Ethiopia, where 
access to healthcare is limited (9). Most of the 
patients with cryptococcal meningitis have serious 
disease and high fatality rate, and its clinical 
symptoms are not typical, misdiagnosis is 
common in early stage (4). 
Each year, Cryptococcus is believed to cause 
more deaths than tuberculosis in Sub-Sahran 
Africa (14-15). Therefore, screening individuals 
with AIDS for serum cryptococcal antigen 
(CrAg), followed by treatment of CrAg positives 
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with antifungals, may prevent cryptococcal 
meningitis (2, 6, 15). In this study, most of the 
participants living with HIV were females 
(54.7%). Similarly, in terims of their age category, 
the majority of HIV patients, 50.4% were in the 
25-36 years group which implies that HIV still 
affects those individuals who are sexually active.  
Moreover, there is a similar report by Kharsany et 
al’s study in which adolescent girls and young 
women aged 15-24 years had up to eight fold 
higher rates of HIV infection compared to their 
male peers. There remains a gap in women 
initiated HIV prevention technologies especially 
for women who are unable to negotiate the current 
HIV prevention options of abstinence, behavior 
change, condoms and medical male circumcision 
or early treatment initiation in their relationships 
(16).  
In this study, we found that the overall 
prevalence of cryptococcal antigenemia was 
11.7% among HIV infected patients with mean 
CD4 count at 51.8 cells/µl. According to Shiferaw 
et al’s study, in Addis Ababa-Ethiopia, the 
magnitude of cryptococcal antigenemia was 11% 
among HIV infected patients with CD4 count 
lessthan100 cells/µl (10). Similarly, according to 
Bitew et al’s. study in Addis Ababa, the 
prevalence of cryptococcal antigenemia among 
HIV positive patients was 8.5% (11).  An overall 
prevalence of 9.9% of C. neoformans infection 
among HIV patients was also documented by 
Egbe et al. in Nigeria (17) which makes our 
finding almost comparable with previous studies 
done in Ethiopia and elsewhere in the world. 
It is indicated that among immunosuppressed 
persons, particularly HIV-infected people with 
CD4 counts under 100, cryptococcal infection is 
important (16) and is one of the AIDS defining 
infections (3). Cryptococcal antigenemia was not 
found associated with patient age group and their 
CD4 count (P>0.05) (Table 2).  On a study done 
in Nigeria, authors demonstrated that CD4 count 
less than 200/µl was significantly associated with 
cryptococcal antigenemia but age group and 
gender did not show association (17). The 
statistical difference on CD4 might be because of 
the small sample size we have employed in the 
present study. 
In this study, we found that the mean CD4 
count of the study participants was 51.8 per 1µl of 
blood (range 3-98). At the same time, all of them 
were stage IV. Considering the fact that in such 
patients with CD4 counts < 100, screening them 
for CrAg and early ART initiation is the most 
important and cost-effective preventive strategy to 
reduce the incidence and high mortality associated 
with cryptococcal meningitis in HIV-infected 
patients (1). Since Amphotericin B is not 
available, the management protocol of CrAg 
positive HIV patients in FHRH was using 
fluconzole based antifungal treatment based on the 
WHO recommended approach (1) and an expert’s 
opinion. The fluconzole based treatment was 
given in three phases: 1) induction phase (for two 
weeks, high dose-600mg BID), 2) consolidation 
phase (for up to eight weeks, 400mg BID) and 3) 
maintenance phase (200mg daily for 3-6 months 
until the patients attains CD4 count of >200). 
Lumber puncture was also given every 24 hours 
for these patients until they got relief from the 
headache.  
The results of our study should be applied 
with caution. Our findings are subject to at least 
two limitations: selection bias and quite limited 
sample size. At the same time, due to the 
retrospective nature of the study, it was not 
possible to show detailed clinical picture of HIV 
patients which might have a significant role to 
indicate the overall profile of the study 
participants. No data was found on the ART status 
and antifungal treatment outcome of patients with 
positive CrAg test. However, our study is the first 
of its kind in the studied area that provide baseline 
information about the magnitude of 
cryptococcosis among HIV positive patients for 
further large scale study. The results of this study 
also showed that this opportunistic fungal 
infection is an important health problem among 
HIV patients that needs the attention of physicians 
who are in charge of attending them.  
In conclusion, althrough we have employed 
quite limited study participants’ data, the reported 
prevalence of cryptococcal antigenemia calls 
stakeholders to expand CrAg screening service for 
individuals with HIV/AIDS, especially for those 
with CD4 count <100/µl. Additional prospective 
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study with adequate sample size is needed to 
determine the exact magnitude of the disease and 
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